Clinical trial · Observational

Biomarkers in Tissue Samples From Patients With Breast Cancer Treated With Bevacizumab

VEGF Gene Amplification/Deletion and Haplotype as Biomarkers for Bevacizumab in Breast Cancer

NCT01156168CI-TRIAL-00027652completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment. PURPOSE: This research study is studying biomarkers in tissue samples from patients with breast cancer treated with bevacizumab.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Breast Cancer	Malignant Breast Neoplasm	CURATED_EXACT	0.92

Interventions

Interventions (6)

Intervention	Type	Mapped drug	Match
DNA analysis	Genetic	—	UNRESOLVED
gene expression analysis	Genetic	—	UNRESOLVED
immunohistochemistry staining method	Other	—	UNRESOLVED
laboratory biomarker analysis	Other	—	UNRESOLVED
polymorphism analysis	Genetic	—	UNRESOLVED
protein expression analysis	Genetic	—	UNRESOLVED

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (1)

measure
Comparison between VEGF haplotype and median overall survival (OS) and grade 3/4 hypertension (HTN)
timeFrame
1 month

Secondary outcomes (1)

measure
Comparison between VEGF amplification/deletion and VEGF expression
timeFrame
1 month

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years
Maximum age: 120 Years

Show eligibility criteria text

DISEASE CHARACTERISTICS:

* Enrolled on ECOG-E2100

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics

References

Publications (0)

Data not yet available

No reference posted for this study.